EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nanomedicine based strategies for oligonucleotide traversion across the blood–brain barrier

Etikala Amulya, Anupama Sikder, Ganesh Vambhurkar, Saurabh Shah, Dharmendra Kumar Khatri, Rajeev Singh Raghuvanshi, Shashi Bala Singh, Saurabh Srivastava

Journal of Controlled Release · 2023

DOI: 10.1016/j.jconrel.2023.01.031 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Etikala Amulya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Res…. Hauptthemen laut MEDLINE: Nanoparticles, Nervous System Diseases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 178 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurological disorders are considered the most prominent cause of disability worldwide. The major hurdle in the management of neurological disorders is the existence of the blood-brain barrier (BBB), which hinders the entry of several therapeutic moieties. In recent years, oligonucleotides have gained tremendous attention for their target specificity, diminished dose and adverse effects, thereby halting disease progression. However, enzymatic degradation, rapid clearance, limited circulation and availability at the bio-active site, etc., limit its clinical translation. Nanomedicine has opened up a breadth of opportunities in the delivery of oligonucleotides across the BBB. This review addresses the pitfalls associated with oligonucleotide delivery in traversing the BBB via nanotherapeutics for the management of brain disorders. Regulatory perspectives pertaining to hastening the clinical translation of oligonucleotide-loaded nanocarriers for brain delivery have been highlighted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesNervous System DiseasesHumansBlood-Brain BarrierNanomedicineOligonucleotidesDrug Delivery Systems

Stichwörter der Autor:innen

Blood–brain barrierCentral nervous systemNanocarriersNeurological disordersOligonucleotidesRegulatory perspectives

Substanzen

Oligonucleotides

Autor:innen und Institutionen

  • Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
  • Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
  • Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government of India, India.
  • Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India. Electronic address: saurabh@niperhyd.…

Zitieren

APA

Amulya, E., Sikder, A., Vambhurkar, G., Shah, S., Khatri, D. K., Raghuvanshi, R. S., Singh, S. B., & Srivastava, S. (2023). Nanomedicine based strategies for oligonucleotide traversion across the blood–brain barrier. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.01.031

Vancouver

Amulya E, Sikder A, Vambhurkar G, Shah S, Khatri DK, Raghuvanshi RS, et al. Nanomedicine based strategies for oligonucleotide traversion across the blood–brain barrier. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.01.031

BibTeX
@article{Amulya2023,
  author = {Amulya, Etikala and Sikder, Anupama and Vambhurkar, Ganesh and Shah, Saurabh and Khatri, Dharmendra Kumar and Raghuvanshi, Rajeev Singh and Singh, Shashi Bala and Srivastava, Saurabh},
  title = {Nanomedicine based strategies for oligonucleotide traversion across the blood–brain barrier},
  journal = {Journal of Controlled Release},
  year = {2023},
  doi = {10.1016/j.jconrel.2023.01.031}
}
Kostenlos starten →